ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

KENGREAL
Thromboembolic disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

KENGREAL Rx

Generic Name and Formulations:
Cangrelor 50mg/vial; lyophilized pwd for IV inj after reconstitution and dilution; contains mannitol, sorbitol.

Company:
The Medicines Company

Therapeutic Use:

Indications for KENGREAL:

As adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Adult:

Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.

Children:

Not established.

Contraindications:

Significant active bleeding.

Warnings/Precautions:

Increased risk of bleeding. Pregnancy (Cat.C). Nursing mothers.

Interactions:

Do not administer clopidogrel or prasugrel during infusion.

Pharmacological Class:

P2Y12 platelet inhibitor (ATP analog).

Adverse Reactions:

Bleeding, renal impairment, dyspnea, hypersensitivity reactions.

Generic Availability:

NO

How Supplied:

Single-use vial (10mL)—1, 10

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs